<DOC>
	<DOCNO>NCT00037089</DOCNO>
	<brief_summary>This study patient esophageal cancer spread area . The purpose study : 1 . Determine well combination taxol , UFT , leucovorin work patient , 2 . Determine survival patient metastatic esophageal carcinoma treat combination drug . 3 . Identify side effect drug combination .</brief_summary>
	<brief_title>A Phase II Study Paclitaxel , UFT , Leucovorin Patients With Metastatic Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>INCLUSION Histologic proof esophageal cancer No one prior nontaxane chemotherapy regimen either treatment localized disease metastatic disease AND may receive regimen contain low dose continuous infusion 5FU ( i.e . &gt; 5 day infusion/cycle ) , capecitabine UFT No prior therapy UFT+/leucovorin , taxane , capecitabine , low dose continuous infusion 5FU ethynyl uracil . Radiographic physical examination documentation metastatic disease No major surgery within 2 week precede start treatment fully recover complication surgery No radiation within 2 week begin chemotherapy . No chemotherapy within 4 week begin treatment . Patients must wait least 6 week receive BCNU MitomycinC . Minimum life expectancy 3 month Informed consent give Laboratory value within limit set study . EXCLUSION More one prior chemotherapy regimen metastatic disease Current serious medical psychiatric illness would prevent informed consent intensive treatment &gt; grade 1 peripheral sensory motor neuropathy Pregnant Patient take drug Sorivudine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2005</verification_date>
</DOC>